FORTRESS BIOTECH INC (FBIO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:FBIO • US34960Q3074

3.67 USD
-0.08 (-2.13%)
At close: Feb 11, 2026
3.71 USD
+0.04 (+1.09%)
Pre-Market: 2/12/2026, 4:01:41 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, FBIO scores 3 out of 10 in our fundamental rating. FBIO was compared to 523 industry peers in the Biotechnology industry. FBIO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, FBIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • FBIO had negative earnings in the past year.
  • FBIO had a negative operating cash flow in the past year.
  • FBIO had negative earnings in each of the past 5 years.
  • FBIO had a negative operating cash flow in each of the past 5 years.
FBIO Yearly Net Income VS EBIT VS OCF VS FCFFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • With an excellent Return On Assets value of -2.94%, FBIO belongs to the best of the industry, outperforming 86.81% of the companies in the same industry.
  • With an excellent Return On Equity value of -9.55%, FBIO belongs to the best of the industry, outperforming 87.95% of the companies in the same industry.
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIO Yearly ROA, ROE, ROICFBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

  • Looking at the Gross Margin, with a value of 71.56%, FBIO belongs to the top of the industry, outperforming 82.41% of the companies in the same industry.
  • In the last couple of years the Gross Margin of FBIO has declined.
  • FBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIO Yearly Profit, Operating, Gross MarginsFBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, FBIO has more shares outstanding
  • Compared to 5 years ago, FBIO has more shares outstanding
  • The debt/assets ratio for FBIO is higher compared to a year ago.
FBIO Yearly Shares OutstandingFBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIO Yearly Total Debt VS Total AssetsFBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • FBIO has an Altman-Z score of -6.01. This is a bad value and indicates that FBIO is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -6.01, FBIO is doing worse than 62.91% of the companies in the same industry.
  • FBIO has a Debt/Equity ratio of 0.86. This is a neutral value indicating FBIO is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.86, FBIO is not doing good in the industry: 72.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Altman-Z -6.01
ROIC/WACCN/A
WACC13.48%
FBIO Yearly LT Debt VS Equity VS FCFFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

  • FBIO has a Current Ratio of 2.19. This indicates that FBIO is financially healthy and has no problem in meeting its short term obligations.
  • FBIO's Current ratio of 2.19 is on the low side compared to the rest of the industry. FBIO is outperformed by 74.19% of its industry peers.
  • FBIO has a Quick Ratio of 1.97. This is a normal value and indicates that FBIO is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.97, FBIO is not doing good in the industry: 74.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.97
FBIO Yearly Current Assets VS Current LiabilitesFBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • FBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.37%, which is quite impressive.
  • FBIO shows a decrease in Revenue. In the last year, the revenue decreased by -0.32%.
  • Measured over the past years, FBIO shows a quite strong growth in Revenue. The Revenue has been growing by 9.50% on average per year.
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%

3.2 Future

  • The Earnings Per Share is expected to grow by 35.19% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 64.44% on average over the next years. This is a very strong growth
EPS Next Y109.83%
EPS Next 2Y41.53%
EPS Next 3Y35.19%
EPS Next 5YN/A
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FBIO Yearly Revenue VS EstimatesFBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIO Yearly EPS VS EstimatesFBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • FBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • FBIO is valuated quite expensively with a Price/Forward Earnings ratio of 359.80.
  • Based on the Price/Forward Earnings ratio, FBIO is valued cheaper than 87.19% of the companies in the same industry.
  • FBIO is valuated expensively when we compare the Price/Forward Earnings ratio to 28.01, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 359.8
FBIO Price Earnings VS Forward Price EarningsFBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIO Per share dataFBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates FBIO does not grow enough to justify the current Price/Earnings ratio.
  • FBIO's earnings are expected to grow with 35.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.53%
EPS Next 3Y35.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for FBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FORTRESS BIOTECH INC

NASDAQ:FBIO (2/11/2026, 8:20:22 PM)

Premarket: 3.71 +0.04 (+1.09%)

3.67

-0.08 (-2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-24
Inst Owners15.2%
Inst Owner Change-5.27%
Ins Owners14.3%
Ins Owner Change1.66%
Market Cap113.92M
Revenue(TTM)62.30M
Net Income(TTM)-5.34M
Analysts82.5
Price Target10.97 (198.91%)
Short Float %18.12%
Short Ratio5.69
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-12.44%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.76%
Min EPS beat(2)-36.17%
Max EPS beat(2)125.68%
EPS beat(4)3
Avg EPS beat(4)24.21%
Min EPS beat(4)-36.17%
Max EPS beat(4)125.68%
EPS beat(8)6
Avg EPS beat(8)23.87%
EPS beat(12)7
Avg EPS beat(12)18.85%
EPS beat(16)9
Avg EPS beat(16)-3.2%
Revenue beat(2)1
Avg Revenue beat(2)-3.53%
Min Revenue beat(2)-17.76%
Max Revenue beat(2)10.71%
Revenue beat(4)2
Avg Revenue beat(4)-1.31%
Min Revenue beat(4)-17.76%
Max Revenue beat(4)10.85%
Revenue beat(8)3
Avg Revenue beat(8)-5.02%
Revenue beat(12)5
Avg Revenue beat(12)3.82%
Revenue beat(16)6
Avg Revenue beat(16)-2.87%
PT rev (1m)0%
PT rev (3m)2.38%
EPS NQ rev (1m)131.88%
EPS NQ rev (3m)125%
EPS NY rev (1m)150%
EPS NY rev (3m)131.82%
Revenue NQ rev (1m)13.07%
Revenue NQ rev (3m)9.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 359.8
P/S 1.83
P/FCF N/A
P/OCF N/A
P/B 2.04
P/tB 4.19
EV/EBITDA N/A
EPS(TTM)-1.62
EYN/A
EPS(NY)0.01
Fwd EY0.28%
FCF(TTM)-2.61
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS2.01
BVpS1.8
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.94%
ROE -9.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.56%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 1.97
Altman-Z -6.01
F-Score4
WACC13.48%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.47%
EPS Next Y109.83%
EPS Next 2Y41.53%
EPS Next 3Y35.19%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.32%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%20.52%
Revenue Next Year24.62%
Revenue Next 2Y36.42%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
EBIT growth 1Y10.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.86%
EBIT Next 3Y23.67%
EBIT Next 5YN/A
FCF growth 1Y42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.14%
OCF growth 3YN/A
OCF growth 5YN/A

FORTRESS BIOTECH INC / FBIO FAQ

What is the fundamental rating for FBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to FBIO.


Can you provide the valuation status for FORTRESS BIOTECH INC?

ChartMill assigns a valuation rating of 2 / 10 to FORTRESS BIOTECH INC (FBIO). This can be considered as Overvalued.


Can you provide the profitability details for FORTRESS BIOTECH INC?

FORTRESS BIOTECH INC (FBIO) has a profitability rating of 2 / 10.


Can you provide the financial health for FBIO stock?

The financial health rating of FORTRESS BIOTECH INC (FBIO) is 2 / 10.


Can you provide the expected EPS growth for FBIO stock?

The Earnings per Share (EPS) of FORTRESS BIOTECH INC (FBIO) is expected to grow by 109.83% in the next year.